One question keeps crossing my mind:
Why did the FDA drag this process out to this point and waste so much of QRX's investor's money if they already knew that Study 022 did not meet its primary endpoint and if they are not willing to approve it on the basis of some of the finer details that have been determined by post-hoc analysis?
Seems like they have just strung us all along.
Add to My Watchlist
What is My Watchlist?